Eloxx Pharmaceuticals Q2 2026 Earnings Results & Report

Eloxx Pharmaceuticals EPS Results

• Actual EPS: -$0.66
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Eloxx Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Eloxx Pharmaceuticals (NASDAQ:ELOX) was a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases caused by nonsense mutations. These mutations can cause cells to stop producing functional proteins, potentially leading to serious inherited disorders.

The company’s lead program, ELX-02, was a synthetic aminoglycoside designed to promote ribosomal read-through of premature stop signals in messenger RNA. Eloxx evaluated ELX-02 in clinical development for genetic conditions including cystinosis and explored its potential in other diseases involving nonsense mutations.

Eloxx also developed ZKN-013, an oral small-molecule program intended to address nonsense-mutation disorders. The company’s research and development activities centered on precision medicines for rare diseases, with clinical and regulatory work directed primarily toward the United States and other major biopharmaceutical markets. Eloxx Pharmaceuticals was historically listed on the Nasdaq under the symbol ELOX.